OverviewSuggest Edit

Pulmonx is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema. It develops the Zephyr Endobronchial Valve, a minimally invasive treatment for chronic obstructive pulmonary disease (COPD). The company also offers the Chartis Pulmonary Assessment system (Chartis System) and the StratX Lung Analysis platform (StratX Platform).
TypePublic
Founded1998
HQRedwood City, CA, US
Websitepulmonx.com

Latest Updates

Employees (est.) (Dec 2020)220(+9%)
Revenue (FY, 2020)$32.7 M
Share Price (Nov 2021)$40.2(-3%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Pulmonx

Glen French

Glen French

President and CEO
Beran Rose

Beran Rose

Chief Commercial Officer
Sri Radhakrishnan

Sri Radhakrishnan

Chief Financial Officer
David Renzi

David Renzi

Senior Vice President, Sales, North America
Lauren Cristina

Lauren Cristina

Vice President, Finance and Administration (U.S.)
Jerome Erath

Jerome Erath

Senior Vice President & General Manager, Europe Middle-East & Africa
Show more

Pulmonx Office Locations

Pulmonx has offices in Redwood City and Neuchâtel
Redwood City, CA, US (HQ)
700 Chesapeake Dr
Neuchâtel, CH
Rue de la Treille 4
Show all (2)

Pulmonx Financials and Metrics

Pulmonx Revenue

Embed Graph
View revenue for all periods
Pulmonx's revenue was reported to be $32.73 m in FY, 2020
USD

Revenue (Q1, 2021)

9.2m

Gross profit (Q1, 2021)

6.6m

Gross profit margin (Q1, 2021), %

71.5%

Net income (Q1, 2021)

(12.0m)

EBIT (Q1, 2021)

(12.0m)

Market capitalization (12-Nov-2021)

1.5b

Closing stock price (12-Nov-2021)

40.2

Cash (31-Mar-2021)

209.3m

EV

1.3b
Pulmonx's current market capitalization is $1.5 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

20.0m32.6m32.7m

Revenue growth, %

63%

Cost of goods sold

7.7m10.2m11.5m

Gross profit

12.3m22.4m21.2m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q4, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

5.8m7.4m9.1m10.3m8.6m3.7m9.2m

Cost of goods sold

2.1m2.4m2.7m3.0m3.0m2.7m2.6m

Gross profit

3.7m5.0m6.4m7.3m5.7m1.0m6.6m

Gross profit Margin, %

64%67%70%71%66%28%72%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

4.1m14.8m231.6m

Accounts Receivable

3.0m5.5m4.2m

Prepaid Expenses

914.0k1.6m3.2m

Inventories

3.3m5.6m10.7m
Quarterly
USDQ2, 2020Q1, 2021

Cash

43.3m209.3m

Accounts Receivable

2.6m5.1m

Prepaid Expenses

1.2m3.0m

Inventories

8.4m11.9m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(18.5m)(20.7m)(32.2m)

Depreciation and Amortization

270.0k365.0k483.0k

Inventories

(1.2m)(2.6m)(5.0m)

Accounts Payable

(648.0k)524.0k592.0k
Quarterly
USDQ2, 2019Q2, 2020Q1, 2021

Net Income

(11.7m)(19.1m)(12.0m)

Depreciation and Amortization

158.0k233.0k141.0k

Inventories

(1.3m)(3.1m)(1.6m)

Accounts Payable

274.0k(769.0k)302.0k
USDFY, 2018

Revenue/Employee

198.2k

Debt/Equity

-0.2 x

Debt/Assets

2.2 x

Financial Leverage

-0.1 x
Show all financial metrics

Pulmonx Operating Metrics

Q2, 2020Sep, 2020

Articles Published

100

Countries Covered (Zephyr Valve)

25

Patients (Zephyr Valve)

20 k

Valves Used

80 k
Show all operating metrics

Pulmonx Revenue Breakdown

Embed Graph

Pulmonx revenue breakdown by geographic segment: 32.8% from United States , 9.9% from Asia Pacific, 56.3% from EMEA and 0.9% from Other

Pulmonx Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

SecurityScorecard logo

Pulmonx Online and Social Media Presence

Embed Graph

Pulmonx News and Updates

Pulmonx to Participate at Upcoming Investor Conferences

REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming virtual investor conferences.

Pulmonx to Present at Upcoming September Investor Conferences

REDWOOD CITY, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) today announced the company will be participating in fireside chats at two upcoming virtual investor conferences. Pulmonx management is scheduled to participate in the 2021 Virtual Wells Fargo He…

Pulmonx Reports Second Quarter 2021 Financial Results

REDWOOD CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the second quarter ended June 30, 2021.

Pulmonx Welcomes Two New Board Members, Adding Expertise in Health Technology, Consumer Marketing, and Integrated Healthcare Delivery Networks

Alissa Hsu Lynch and Tiffany Sullivan join the Pulmonx Board of Directors Alissa Hsu Lynch and Tiffany Sullivan join the Pulmonx Board of Directors

Pulmonx Corporation Expands Leadership Team

REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the appointment of Michael Ryan as Vice President, Corporate Strategy and Business Development, and the ea…

Pulmonx Reports Fourth Quarter and Full Year 2020 Financial Results

REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2020 ended December 31, 2020.
Show more

Pulmonx Frequently Asked Questions

  • When was Pulmonx founded?

    Pulmonx was founded in 1998.

  • Who are Pulmonx key executives?

    Pulmonx's key executives are Glen French, Beran Rose and Sri Radhakrishnan.

  • How many employees does Pulmonx have?

    Pulmonx has 220 employees.

  • What is Pulmonx revenue?

    Latest Pulmonx annual revenue is $32.7 m.

  • What is Pulmonx revenue per employee?

    Latest Pulmonx revenue per employee is $148.8 k.

  • Who are Pulmonx competitors?

    Competitors of Pulmonx include Sanovas, Caldera Medical and Nuvaira.

  • Where is Pulmonx headquarters?

    Pulmonx headquarters is located at 700 Chesapeake Dr, Redwood City.

  • Where are Pulmonx offices?

    Pulmonx has offices in Redwood City and Neuchâtel.

  • How many offices does Pulmonx have?

    Pulmonx has 2 offices.